NPS Q1 2026 Portfolio — Raises NVDA & AAPL, Exits MRSH Entirely
Korea's National Pension Service disclosed a $58.4B portfolio in its Q1 2026 13F filing, aggressively adding to NVDA, AAPL, and MSFT while fully liquidating positions including MRSH.

- NPS disclosed a $58.4B portfolio in Q1 2026, adding to NVDA ($8.9B, +2%) and AAPL ($7.9B, +3%)
- The fund fully exited MRSH ($212M) and CYBR in its largest liquidations of the quarter
The National Pension Service (NPS) revealed a $58.4B portfolio in its Q1 2026 13F filing. The fund increased exposure across NVDA ($8.9B, +2%), AAPL ($7.9B, +3%), and MSFT ($5.5B, +3%), deepening its concentration in big tech, while fully exiting MRSH (approximately $212M).

Top 5 Holdings — Q1 2026
Q1 2026 Key Portfolio Moves
NPS's Q1 2026 portfolio reflects a clear high-conviction big tech concentration strategy. Top holding NVDA expanded to a 6.8% weighting ($8.9B), up 2 percentage points quarter-over-quarter, while AAPL ($7.9B) and MSFT ($5.5B) each grew by 3 percentage points. The top 10 holdings are heavily skewed toward AI, semiconductors, and platform names — including AMZN ($4.3B), GOOGL ($3.7B), AVGO ($2.9B), and META ($2.7B). The top three positions alone (NVDA, AAPL, MSFT) account for 17% of the total portfolio.
- NVDA: Increased +2% ($8.9B) — Solidified as the top holding, reinforcing NPS's core AI semiconductor conviction
- AAPL: Increased +3% ($7.9B) — Aggressively built up the global consumer platform flagship, retaining the #2 position
- MRSH: Full exit ($212M → $0) — Largest liquidation of the quarter, signaling clear risk management intent
- CYBR: Full exit ($70M → $0) — Complete removal of cybersecurity sector exposure, reinforcing sector concentration
- ROYALTY PHARMA PLC: New position ($36M) — Small-scale entry into the healthcare royalty model as a diversification move
On the buy side, new positions in Royalty Pharma PLC ($36M) and Amcor PLC ($20M) stand out as modest diversification moves into healthcare royalties and packaging materials. On the sell side, the full liquidation of MRSH ($212M) was the most significant action of the quarter, followed by a complete exit from CYBR ($70M). Notable trims include EQH (-96%), BAX (-94%), and GLPI (-93%), all reduced to near-zero levels — further evidence of an accelerating portfolio concentration trend.
Will the Big Tech Concentration Strategy Continue?
NPS maintained its high-conviction AI, semiconductor, and big tech concentration strategy through Q1 2026. With the top three holdings — NVDA, AAPL, and MSFT — now exceeding a combined 17% weighting, the fund has further sharpened its focus by decisively exiting non-core positions such as MRSH and CYBR. Looking ahead, earnings visibility for AI-driven beneficiaries and shifts in the global rate environment will be the key variables shaping the portfolio's next repositioning. It remains to be seen whether small-scale healthcare additions like Royalty Pharma will serve as the foundation for a longer-term sector diversification effort.
Frequently Asked Questions
What new positions did NPS initiate in Q1 2026?
NPS opened five new positions in Q1 2026: Royalty Pharma PLC ($36M), Amcor PLC ($20M), LITE ($3M), OKTA ($3M), and SOLV ($2M).
What was the biggest portfolio change for NPS in Q1 2026?
The most significant change was the full liquidation of MRSH (approximately $212M). Simultaneously, NPS raised its weightings in NVDA, AAPL, and MSFT by 2–3 percentage points each, reinforcing its big tech concentration strategy.
What is NPS's largest holding?
As of Q1 2026, NPS's largest holding is NVDA at $8.9B, representing 6.8% of the portfolio — up 2 percentage points from the prior quarter.
What is the NPS U.S. equity AUM?
Based on the Q1 2026 13F filing, NPS's U.S. equity portfolio AUM stands at approximately $58.4B across 20 holdings.
Smart Money Briefing
Weekly summaries of Wall Street guru moves and crypto whale activity.




